Tolterodine: a new drug for urinary incontinence

Abstract

Urinary incontinence is estimated to affect more than 30 million people in the developed world. However, while this disorder is treatable and often curable in most individuals, the efficacy and tolerability of currently available therapeutic agents is far from optimal. Tolterodine ^* is a new muscarinic antagonist specifically developed for the treatment of urinary urge incontinence and other symptoms of detrusor overactivity. In this week’s issue, Inpharma ® maps the progress of this interesting compound in preclinical studies and preliminary phase II clinical trials.